Benzinga | Oct 7, 2021 08:09AM EDT

Outlook Therapeutics To Present At The 2021 American Society Of Retina Specialists Annual Meeting

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that Suber S. Huang, MD, MBA, FASRS, Co-Founder and CEO of the Retina Center of Ohio, will present data from Outlook Therapeutics' NORSE THREE supplemental safety study for ONS-5010 / LYTENAVA(tm) (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. Dr. Huang's oral presentation will take place at the 2021 Annual Meeting of the American Society of Retina Specialists being held in San Antonio, Texas.

Details for the presentation are as follows:

Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients with Wet AMD, DME and BRVO

Presenter: Suber S. Huang, MD, MBA, FASRS

Date and time: October 12, 2021, at 11:08-11:14 AM CDT

For more information and to register for this event, please visit https://www.asrs.org/annual-meeting.